← Browse by Condition
Medical Condition

advanced solid tumor

Total Trials
37
Recruiting Now
37
Trial Phases
Phase 1, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for advanced solid tumor sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — advanced solid tumor Clinical Trials

How many clinical trials are currently recruiting for advanced solid tumor?
ClinicalMetric currently tracks 37 actively recruiting clinical trials for advanced solid tumor, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 37. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for advanced solid tumor?
advanced solid tumor research spans Phase 1 (35 trials), Phase 2 (16 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a advanced solid tumor clinical trial?
Eligibility criteria for advanced solid tumor trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
35
Phase 2
16
Top Sponsors
BeOne Medicines 3 trials
Ascentage Pharma Group Inc. 2 trials
Daiichi Sankyo 2 trials
Fate Therapeutics 1 trial
China-Japan Friendship Hospital 1 trial

Recruiting Clinical Trials

NCT07226349 Phase 1
Recruiting
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
Enrollment
105 pts
Location
United States, Austr...
Sponsor
BeOne Medicines
View Trial →
NCT06687070 Phase 1
Recruiting
APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
Enrollment
90 pts
Location
China
Sponsor
Ascentage Pharma Group Inc.
View Trial →
NCT06241456 Phase 1
Recruiting
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Enrollment
351 pts
Location
United States
Sponsor
Fate Therapeutics
View Trial →
NCT06173219 Phase 1, Phase 2
Recruiting
Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Malignant Tumors.
Enrollment
38 pts
Location
China
Sponsor
China-Japan Friendship Hospita...
View Trial →
NCT05103683 Phase 1
Recruiting
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
Enrollment
90 pts
Location
United States, South...
Sponsor
TORL Biotherapeutics, LLC
View Trial →
NCT06187402 Phase 1, Phase 2
Recruiting
A Study of LM-24C5 For Advanced Solid Tumors
Enrollment
49 pts
Location
United States
Sponsor
LaNova Medicines Limited
View Trial →
NCT04785196 Phase 1, Phase 2
Recruiting
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Enrollment
95 pts
Location
China
Sponsor
Ascentage Pharma Group Inc.
View Trial →
NCT05701150
Recruiting
AIO-BNHO Comprehensive Clinico-genomics Database Network - AIO-BNHO CONNECT
Enrollment
3,000 pts
Location
Germany
Sponsor
AIO-Studien-gGmbH
View Trial →
NCT05661461 Phase 1
Recruiting
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
Enrollment
28 pts
Location
United States
Sponsor
Aadi Bioscience, Inc.
View Trial →
NCT07414836 Phase 1
Recruiting
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
Enrollment
84 pts
Location
United States, Austr...
Sponsor
BeOne Medicines
View Trial →
NCT07181681 Phase 1
Recruiting
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
Enrollment
63 pts
Location
United States, Austr...
Sponsor
BeOne Medicines
View Trial →
NCT07811037 Phase 1, Phase 2
Recruiting
A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Immunogenicity, and Preliminary Efficacy of SGT003 in Patients With Advanced Solid Tumors
Enrollment
332 pts
Location
China
Sponsor
Beijing Sungen Biomedical Tech...
View Trial →
NCT05142423 Phase 1, Phase 2
Recruiting
A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors
Enrollment
198 pts
Location
China
Sponsor
Akeso
View Trial →
NCT06484816 Phase 1
Recruiting
TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
Enrollment
90 pts
Location
China
Sponsor
Shenzhen TargetRx Co., Ltd.
View Trial →
NCT06634849 Phase 1, Phase 2
Recruiting
An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).
Enrollment
30 pts
Location
Australia
Sponsor
Pathios Therapeutics Pty Ltd
View Trial →
NCT07380334 Phase 1
Recruiting
A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid Tumors
Enrollment
200 pts
Location
China
Sponsor
Jiangsu HengRui Medicine Co., ...
View Trial →
NCT05875168 Phase 1, Phase 2
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Enrollment
590 pts
Location
United States, Belgi...
Sponsor
Daiichi Sankyo
View Trial →
NCT05892718 Phase 1
Recruiting
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
Enrollment
80 pts
Location
United States, China...
Sponsor
FBD Biologics Limited
View Trial →
NCT04104776 Phase 1, Phase 2
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Enrollment
300 pts
Location
United States, Franc...
Sponsor
Novartis Pharmaceuticals
View Trial →
NCT05269316 Phase 1, Phase 2
Recruiting
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Enrollment
61 pts
Location
United States, Austr...
Sponsor
Impact Therapeutics, Inc.
View Trial →
NCT06669975 Phase 1, Phase 2
Recruiting
A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors
Enrollment
85 pts
Location
Australia
Sponsor
AP Biosciences Inc.
View Trial →
NCT06242470 Phase 1
Recruiting
A Study of MGC026 in Participants With Advanced Solid Tumors
Enrollment
250 pts
Location
United States, Austr...
Sponsor
MacroGenics
View Trial →
NCT06154291 Phase 1, Phase 2
Recruiting
FIH XON7 in Advanced/Metastatic Solid Tumors
Enrollment
255 pts
Location
Belgium, France
Sponsor
Xenothera SAS
View Trial →
NCT07284186 Phase 1
Recruiting
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Enrollment
155 pts
Location
United States
Sponsor
Plexium, Inc.
View Trial →
NCT05873686 Phase 1
Recruiting
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Enrollment
140 pts
Location
United States, Unite...
Sponsor
Nuvectis Pharma, Inc.
View Trial →
NCT06132503 Phase 1
Recruiting
Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
Enrollment
110 pts
Location
United States
Sponsor
Lantern Pharma Inc.
View Trial →
NCT06126666 Phase 1
Recruiting
A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors
Enrollment
96 pts
Location
South Korea
Sponsor
ABL Bio, Inc.
View Trial →
NCT07213830 Phase 1, Phase 2
Recruiting
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
Enrollment
102 pts
Location
United States, Canad...
Sponsor
Ipsen
View Trial →
NCT05765851 Phase 1
Recruiting
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
Enrollment
108 pts
Location
United States, Canad...
Sponsor
Daiichi Sankyo
View Trial →
NCT07110883 Phase 1
Recruiting
A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors
Enrollment
400 pts
Location
China
Sponsor
CSPC Megalith Biopharmaceutica...
View Trial →
NCT06028724
Recruiting
A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
Enrollment
782 pts
Location
Italy
Sponsor
Centro di Riferimento Oncologi...
View Trial →
NCT06959615 Phase 1, Phase 2
Recruiting
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
Enrollment
334 pts
Location
China
Sponsor
Jacobio Pharmaceuticals Co., L...
View Trial →
NCT06223256 Phase 1
Recruiting
A Study of NBL-028 in Patients With Advanced Solid Tumors
Enrollment
270 pts
Location
China
Sponsor
NovaRock Biotherapeutics, Ltd
View Trial →
NCT04390737 Phase 1, Phase 2
Recruiting
Evaluate the Safety and Clinical Activity of HH2853
Enrollment
254 pts
Location
United States, China
Sponsor
Haihe Biopharma Co., Ltd.
View Trial →
NCT06332170 Phase 1
Recruiting
ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors
Enrollment
610 pts
Location
China
Sponsor
Hansoh BioMedical R&D Company
View Trial →
NCT05320588 Phase 1, Phase 2
Recruiting
A Study in Patients With Advanced Cancers
Enrollment
332 pts
Location
United States
Sponsor
BiOneCure Therapeutics Inc.
View Trial →
NCT05417321 Phase 1, Phase 2
Recruiting
A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors
Enrollment
80 pts
Location
United States, China
Sponsor
Shanghai Huaota Biopharmaceuti...
View Trial →

Related Conditions

endometrial cancer (4) ovarian cancer (3) metastatic solid tumor (3) nsclc (2) non small cell lung cancer (2) solid tumor (2) advanced cancer (2) metastatic cancer (2) melanoma (2) cervical cancer (2) gastric cancer (2) breast cancer (2)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology